Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetirizine Hydrochloride Injection for Acute Urticaria
NCT06819774Phase 3Recruiting
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Apr 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cetirizine in acute urticaria (2 arms), sponsored by Shandong New Time Pharmaceutical. Primary endpoint: Scoring of the severity of pruritus at 2 hours. Started Apr 2024; status: recruiting.
02
Drugs
cetirizine
03
Conditions
acute urticaria
Beyond the preview
Go deeper on NCT06819774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06819774.